Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New procedure targets nerves to stop heart rhythm chaos

NCT ID NCT07501819

Disease control Sponsor: SymKardia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a procedure that uses a catheter to ablate (destroy) a nerve near the heart, aiming to reduce signals that trigger ventricular tachycardia (VT), a dangerous fast heart rhythm. Ten adults with an implanted defibrillator (ICD) and recurrent VT will be enrolled. The main goals are to check safety and see if the procedure lowers the number of VT episodes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter-based ablation of a sympathetic nerve near the heart
What this could lead to
If it works, this could offer a new way to control dangerous heart rhythms without long-term medication.
What could go wrong
This is a very early, small study (10 people) testing safety and feasibility, so it may not lead to a proven treatment. Risks include procedure-related complications like bleeding or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 or older at the time of informed consent 2. Willing and capable of providing written informed consent 3. Implanted ICD or CRT-D 4. Recurrent VT leading to ICD therapy (ATP or shock) 5. Indicated for catheter ablation of VT per international guidelines 6. No prior instrumentation or resection of the stellate ganglia, or surgical procedure that may have disturbed the stellate ganglia Exclusion Criteria: 1. Contraindication to percutaneous femoral arterial access 2. Heparin-induced thrombotic thrombocytopenia 3. Prior surgical sympathectomy 4. ECMO therapy in the past 30 days 5. Contraindicated for advanced heart failure therapies (LVAD or heart transplantation) 6. A most recently documented LVEF \<20% in the past 30 days 7. Receiving inotropic drug therapy 8. Women of childbearing potential who are pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test at enrollment 9. A life expectancy of less than 12 months according to physician judgment 10. Involvement in any concurrent clinical study with an investigational therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventricular tachycardia (VT) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ventricular tachycardia (VT)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.